Digital gamma camera developer Digirad of San Diego hasfiled forregulatory clearance with the Food and Drug Administration forits lead product, Notebook Imager. If and when the applicationis cleared, Notebook Imager will become the first solid-stategamma
Digital gamma camera developer Digirad of San Diego hasfiled forregulatory clearance with the Food and Drug Administration forits lead product, Notebook Imager. If and when the applicationis cleared, Notebook Imager will become the first solid-stategamma camera to be marketed commercially.
Notebook Imager is a portable gamma camera that uses a cadmiumzinc telluride detector array rather than scintillation crystalsand photomultiplier tubes, as conventional Anger-style camerasdo (SCAN 6/5/96). Digirad hopes to receive FDA clearance and beginmarketing the system next year.
To help ramp up its manufacturing and product-testing effort,Digirad completed a $6 million financing issued to a group ofventure-capital firms. Proceeds from the funding will be usedto finish beta-site testing and develop a manufacturing capacityfor Notebook Imager. The funding was led by Sorrento Ventures,and included Kingsbury Capital Partners and several individualinvestors.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.